Merck in talks to pay about $30B for Revolution Medicines, WSJ says

Merck (MRK) is in talks to acquire Revolution Medicines (RVMD) in a deal that could value it at around $30B as the pharma giant has been discussing a deal valued between $28B and $32B, people familiar with the matter told The Wall Street Journal’s Lauren Thomas and Jonathan Rockoff. A deal for the cancer-drug biotech could come as soon as later this month, said the sources. The Financial Times also reported Thursday that Merck was discussing a deal with Revolution in that price range.